G-protein coupled receptor and uses therefor

• US 20070031860A1
• Filed: 04/03/2006
• Published: 02/08/2007
• Est. Priority Date: 06/07/2001
• Status: Abandoned Application

• Current Assignee: Wyeth (Pfizer Inc.)
• Original Assignee: Wyeth (Pfizer Inc.)
• Inventors: Bates, Brian, Blatcher, Maria, Paulsen, Janet
• Application Number:
  US11/396,960
• Publication Number:
  US 20070031860A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: A01K 2217/075 inducing loss of function, i.e. knock out
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C07K 14/70571 for neuromediators, e.g. serotonin receptor, dopamine receptor

Abstract

The present invention is based on the identification of a G-protein coupled receptor (GPCR) that is expressed predominantly in the brain and placenta and nucleic acid molecules that encoded the GPCR, which is referred to herein as the hCAR protein and hCAR gene respectively (for human Constitutively Active Receptor). Based on this identification, the present invention provides: (1) isolated hCAR protein; (2) isolated nucleic acid molecules that encode an hCAR protein; (3) antibodies that selectively bind to the hCAR protein; (4) methods of isolating allelic variants of the hCAR protein and gene; (5) methods of identifying cells and tissues that express the hCAR protein/gene; (6) methods of identifying agents and cellular compounds that bind to the hCAR protein; (7) methods of identifying agents that modulate the expression of the hCAR gene; and (8) methods of modulating the activity of the hCAR protein in a cell or organism.

Claims

1-12. -12. (canceled)

13. An isolated hCAR protein comprising the amino acid sequence of SEQ ID NO:

2.

16. The protein of claim 13 further comprising heterologous amino acid sequences.

17. An antibody which selectively binds to a protein of claim 13.

14. An isolated peptide comprising an extracellular domain of the hCAR protein.

15. A peptide according to claim 14 comprising a sequence selected from the group consisting of SEQ ID NOs:

4, 5, 6, and 7.

18. An antibody which selectively binds to a peptide according to claim 14.

19. An antibody which selectively binds to a peptide according to claim 15.

20-29. -29. (canceled)

30. A method for the treatment of a patient having need of the inhibition of hCAR activity, such treatment comprising administering to the patient a therapeutically effective amount of an antibody which binds to an extracellular portion of hCAR.

31-41. -41. (canceled)